Hatim Husain, MD

A panelist discusses how the MARIPOSA, SKIPPirr, and COCOON studies highlight the significant overall survival benefit of the amivantamab and lazertinib combination in first-line treatment for EGFR-mutant non–small cell lung cancer (NSCLC), while also emphasizing the importance of proactive management of adverse events (AEs), which may shift the standard of care and improve patient tolerability and adherence.

A panelist discusses how strategies such as clear patient education, simplified skin care regimens, personalized recommendations, and regular follow-ups, along with family involvement and addressing barriers to adherence, can significantly improve patient adherence to prophylactic dermatologic care, leading to better management of dermatologic adverse events (DAEs) in cancer treatment.

A panelist discusses how proactive management of dermatologic adverse events (DAEs) in cancer treatment, through early detection, tailored interventions, and collaboration with specialists such as dermatologic oncologists, advanced practice providers (APPs), and pharmacists, significantly enhances patient comfort, treatment adherence, and overall outcomes.

A panelist discusses how the COCOON study's findings will lead to the integration of enhanced dermatologic management into clinical practice for patients receiving amivantamab and lazertinib, focusing on proactive care to reduce dermatologic adverse events (DAEs), improve patient comfort, and increase treatment adherence, ultimately optimizing patient outcomes.

A panelist discusses how prophylactic dermatologic management, including the proactive use of moisturizers, topical steroids, and antibiotics, significantly improves the tolerability and adherence to first-line treatment with amivantamab and lazertinib for advanced non–small cell lung cancer (NSCLC) by reducing the severity of dermatologic adverse events (DAEs) and preventing treatment interruptions.

A panelist discusses how the COCOON study demonstrated that enhanced dermatologic management significantly reduces the incidence and severity of dermatologic adverse events (DAEs) in patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) receiving first-line treatment with amivantamab and lazertinib, improving both quality of life and treatment adherence.

A panelist discusses how first-line (1L) therapies, including EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib, are the standard of care for treating locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC), with emerging combination strategies and safety considerations shaping current treatment approaches.

Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists for optimizing patient care in this rapidly changing field.

Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, including prophylactic antibiotics, good skin hygiene, and insights from the phase 2 COCOON study, can help manage potential adverse effects and improve treatment outcomes.

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for Medical Oncology Congress 2024, affect treatment strategies for patients with non–small cell lung cancer that has developed resistance to osimertinib.

Panelist discusses how an early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab plus lazertinib vs osimertinib was presented at the European Society for Medical Oncology Congress 2024, shedding light on potential strategies for managing EGFR-mutated and MET-amplified non–small cell lung cancer.

Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, are now being used proactively to prevent drivers of disease progression.

Hatim Husain, MD, discusses how acquired resistance to kinase inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC) poses a significant challenge in long-term treatment efficacy, necessitating ongoing research into novel therapeutic strategies and combination approaches to overcome resistance mechanisms.

Discuss emerging data and therapies to optimize future treatment.

Overview of side effects and management when combining these agents.

Highlight key findings in the KRYSTAL-7 trial.

Analyze the appropriate washout period when switching between KRAS inhibitors.

Review evidence on sequencing of KRAS inhibitors after progression on the initial treatment.

Address the challenges and recommended approaches for managing the patient’s untreated brain metastases.

Discuss the role of molecular profiling and KRAS G12C testing in guiding treatment decisions of this case.

Assess whether the initial therapy aligned with standard guidelines based on disease stage.

Provide an overview of the patient's presentation, diagnosis, and initial treatment plan.

Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses a study monitoring the emergence of<em> T790M </em>in <em>EGFR</em>-mutated non-small cell lung cancer (NSCLC).